American College of Rheumatology includes Vectra in new recommendations on disease activity measures for rheumatoid arthritis.

“We have updated prior ACR recommendations for preferred RA disease activity measures, identifying 11 measures that met a minimum standard for regular use…”

England BR, et al. 2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures. Arthritis Care Res. 2019 Nov 11.

View Article

Compared methotrexate with other DMARD or combination of DMARDs for treatments of interest.

“Triple therapy (methotrexate plus sulfasalazine plus hydroxychloroquine) and most regimens combining biologic DMARDs with methotrexate were effective in controlling disease activity, and all were generally well tolerated in both methotrexate naive and methotrexate exposed patients.”

Hazlewood GS, et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ 2016, 353:i1777.

View Article

Mavrilimumab evaluated in a phase 2 randomized, double-blind, placebo-controlled study.

“Mavrilimumab [a human monoclonal antibody] induced rapid clinically significant responses in RA subjects, suggesting that inhibiting the mononuclear phagocyte pathway may provide a novel therapeutic approach for RA.”

Burmester GR, et al. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis. 2013; 72(9):1445-1452.

View Article